Positive recommendation for Truberzi from NICE for IBS-D in adults

27 July 2017

Ireland-incorporated Allergan (NYSE: AGN) said today that the National Institute of Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD), recommending that Truberzi (eluxadoline) be made available on the National Health Service for adults living with irritable bowel syndrome with diarrhea (IBS-D).

The NICE commented that its independent committee heard that IBS-D can have a significant impact on a person’s quality of life, and having Truberzi as an option would be welcomed by patients.

The committee concluded that Truberzi can improve stool consistency, result in less pain and improve quality of life. It is estimated that it costs £3 ($3.92) per patient per day. The committee concluded that Truberzi was a cost-effective use of National Health Service resources.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK